Future Directions in Osteoporosis Therapeutics

被引:24
|
作者
Bone, Henry [1 ]
机构
[1] St John Hosp & Med Ctr, Michigan Bone & Mineral Clin, Sect Endocrinol & Metab, Detroit, MI 48236 USA
关键词
Osteoporosis; Osteocytes; Antiresorptives; Anabolic agents; CATHEPSIN-K INHIBITOR; POSTMENOPAUSAL WOMEN; PARATHYROID-HORMONE; BONE MASS; AMERICAN-SOCIETY; TASK-FORCE; ESTROGEN; ALENDRONATE; PREVENTION; FRACTURES;
D O I
10.1016/j.ecl.2012.05.003
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Future directions in osteoporosis treatment will include development of medications with increasingly precise mechanistic targets, including the RANK-ligand pathway, cathepsin K inhibition, and Wnt signaling manipulation. More gains are likely with anabolics and newer antiresorptives that cause little or no suppression of formation. Optimal treatment of osteoporosis may require coordination of anabolic and antiresorptive treatment, following stimulation of bone formation with consolidation and long-term maintenance. Some well-established drugs may be useful in such regimens. We can also anticipate emphasis on cost containment using currently available drugs, especially as they become generic. Effective implementation and treatment continuity will be important themes.
引用
收藏
页码:655 / +
页数:8
相关论文
共 50 条
  • [31] The Metaverse for Healthcare: Trends, Applications, and Future Directions of Digital Therapeutics for Urology
    Kim, Eun Joung
    Kim, Jung Yoon
    [J]. INTERNATIONAL NEUROUROLOGY JOURNAL, 2023, 27 : S3 - S12
  • [32] Characterization of protein therapeutics by mass spectrometry: recent developments and future directions
    Chen, Guodong
    Warrack, Bethanne M.
    Goodenough, Angela K.
    Wei, Hui
    Wang-Iverson, David B.
    Tymiak, Adrienne A.
    [J]. DRUG DISCOVERY TODAY, 2011, 16 (1-2) : 58 - 64
  • [33] Novel agents for pancreatic ductal adenocarcinoma: emerging therapeutics and future directions
    Yiyin Zhang
    Chao Yang
    He Cheng
    Zhiyao Fan
    Qiuyi Huang
    Yu Lu
    Kun Fan
    Guopei Luo
    Kaizhou Jin
    Zhengshi Wang
    Chen Liu
    Xianjun Yu
    [J]. Journal of Hematology & Oncology, 11
  • [34] Novel agents for pancreatic ductal adenocarcinoma: emerging therapeutics and future directions
    Zhang, Yiyin
    Yang, Chao
    Cheng, He
    Fan, Zhiyao
    Huang, Qiuyi
    Lu, Yu
    Fan, Kun
    Luo, Guopei
    Jin, Kaizhou
    Wang, Zhengshi
    Liu, Chen
    Yu, Xianjun
    [J]. JOURNAL OF HEMATOLOGY & ONCOLOGY, 2018, 11
  • [35] Future directions of liposome- and immunoliposome-based cancer therapeutics
    Park, JW
    Benz, CC
    Martin, FJ
    [J]. SEMINARS IN ONCOLOGY, 2004, 31 (06) : 196 - 205
  • [36] RNA-based therapeutics for colorectal cancer: Updates and future directions
    Liu, Jingwen
    Guo, Bin
    [J]. PHARMACOLOGICAL RESEARCH, 2020, 152
  • [37] Periodontal therapeutics: Current host-modulation agents and future directions
    Golub, Lorne M.
    Lee, Hsi-Ming
    [J]. PERIODONTOLOGY 2000, 2020, 82 (01) : 186 - 204
  • [38] Engineering the protein corona: Strategies, effects, and future directions in nanoparticle therapeutics
    Zhao, Tianyu
    Ren, Mingli
    Shi, Jiajie
    Wang, Haijiao
    Bai, Jing
    Du, Wenli
    Xiang, Bai
    [J]. BIOMEDICINE & PHARMACOTHERAPY, 2024, 175
  • [39] New therapeutics for osteoporosis
    Ng, Kong Wah
    Martin, T. John
    [J]. CURRENT OPINION IN PHARMACOLOGY, 2014, 16 : 58 - 63
  • [40] Therapeutics issues in osteoporosis
    Perez, Adolfo Diez
    [J]. MEDICINA CLINICA, 2007, 129 (20): : 773 - 774